Cargando…

Long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure: a retrospective study

BACKGROUND: The long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure (HBV-ACLF) is not well characterised. We assessed long-term outcomes and the associated risk factors of HBV-ACLF patients in southern China. METHODS: We retrospectively analysed clinical dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lu, Xu, Wenxiong, Li, Xuejun, Chen, Dabiao, Zhang, Yeqiong, Chen, Yuanli, Wang, Juan, Luo, Qiumin, Xie, Chan, Peng, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976971/
https://www.ncbi.nlm.nih.gov/pubmed/35366805
http://dx.doi.org/10.1186/s12876-022-02239-4
_version_ 1784680677228150784
author Wang, Lu
Xu, Wenxiong
Li, Xuejun
Chen, Dabiao
Zhang, Yeqiong
Chen, Yuanli
Wang, Juan
Luo, Qiumin
Xie, Chan
Peng, Liang
author_facet Wang, Lu
Xu, Wenxiong
Li, Xuejun
Chen, Dabiao
Zhang, Yeqiong
Chen, Yuanli
Wang, Juan
Luo, Qiumin
Xie, Chan
Peng, Liang
author_sort Wang, Lu
collection PubMed
description BACKGROUND: The long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure (HBV-ACLF) is not well characterised. We assessed long-term outcomes and the associated risk factors of HBV-ACLF patients in southern China. METHODS: We retrospectively analysed clinical data, adverse events, and clinical endpoint events of HBV-ACLF patients treated at our department between January 2014 and December 2018. RESULTS: A total of 616 (52.3%) patients with cirrhosis and 561 (47.7%) patients without cirrhosis were included. In 973 (83%) patients, the disease was associated only with HBV, while 204 (17%) patients had two or more aetiological factors. The proportion of patients receiving antiviral treatment for HBV was low (20.3%). Further analyses indicated that patients without cirrhosis had a significantly lower 90-day liver transplantation–free mortality and higher 5‐year survival rate than those with cirrhosis (59.5% vs. 27.6%; 62% vs. 36%; P < 0.05). Remarkably, self-withdrawal of nucleos(t)ide analog (NA) was an independent risk factor for short-term prognosis. Age, cirrhosis at admission, and platelet level were closely related to long-term prognosis of HBV-ACLF patients. CONCLUSION: The proportion of HBV-ACLF patients receiving antiviral treatment is very low in south China. Cirrhosis at admission has a significant effect on both short-term and long-term prognosis. No significant improvement in the short-term prognosis of HBV-ACLF patients was observed compared with previous studies. More comprehensive access to antiviral treatment and long-term surveillance of HBV patients are key imperatives to reduce the incidence of HBV-ACLF and improve the prognosis. Trial Registration The trial was registered at ClinicalTrials.gov (CT.gov identifier: NCT04231565) on May 13, 2020: https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0009OZY&selectaction=Edit&uid=U00036P1&ts=2&cx=27seqt
format Online
Article
Text
id pubmed-8976971
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89769712022-04-04 Long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure: a retrospective study Wang, Lu Xu, Wenxiong Li, Xuejun Chen, Dabiao Zhang, Yeqiong Chen, Yuanli Wang, Juan Luo, Qiumin Xie, Chan Peng, Liang BMC Gastroenterol Research BACKGROUND: The long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure (HBV-ACLF) is not well characterised. We assessed long-term outcomes and the associated risk factors of HBV-ACLF patients in southern China. METHODS: We retrospectively analysed clinical data, adverse events, and clinical endpoint events of HBV-ACLF patients treated at our department between January 2014 and December 2018. RESULTS: A total of 616 (52.3%) patients with cirrhosis and 561 (47.7%) patients without cirrhosis were included. In 973 (83%) patients, the disease was associated only with HBV, while 204 (17%) patients had two or more aetiological factors. The proportion of patients receiving antiviral treatment for HBV was low (20.3%). Further analyses indicated that patients without cirrhosis had a significantly lower 90-day liver transplantation–free mortality and higher 5‐year survival rate than those with cirrhosis (59.5% vs. 27.6%; 62% vs. 36%; P < 0.05). Remarkably, self-withdrawal of nucleos(t)ide analog (NA) was an independent risk factor for short-term prognosis. Age, cirrhosis at admission, and platelet level were closely related to long-term prognosis of HBV-ACLF patients. CONCLUSION: The proportion of HBV-ACLF patients receiving antiviral treatment is very low in south China. Cirrhosis at admission has a significant effect on both short-term and long-term prognosis. No significant improvement in the short-term prognosis of HBV-ACLF patients was observed compared with previous studies. More comprehensive access to antiviral treatment and long-term surveillance of HBV patients are key imperatives to reduce the incidence of HBV-ACLF and improve the prognosis. Trial Registration The trial was registered at ClinicalTrials.gov (CT.gov identifier: NCT04231565) on May 13, 2020: https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0009OZY&selectaction=Edit&uid=U00036P1&ts=2&cx=27seqt BioMed Central 2022-04-02 /pmc/articles/PMC8976971/ /pubmed/35366805 http://dx.doi.org/10.1186/s12876-022-02239-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Lu
Xu, Wenxiong
Li, Xuejun
Chen, Dabiao
Zhang, Yeqiong
Chen, Yuanli
Wang, Juan
Luo, Qiumin
Xie, Chan
Peng, Liang
Long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure: a retrospective study
title Long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure: a retrospective study
title_full Long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure: a retrospective study
title_fullStr Long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure: a retrospective study
title_full_unstemmed Long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure: a retrospective study
title_short Long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure: a retrospective study
title_sort long-term prognosis of patients with hepatitis b virus–related acute-on-chronic liver failure: a retrospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976971/
https://www.ncbi.nlm.nih.gov/pubmed/35366805
http://dx.doi.org/10.1186/s12876-022-02239-4
work_keys_str_mv AT wanglu longtermprognosisofpatientswithhepatitisbvirusrelatedacuteonchronicliverfailurearetrospectivestudy
AT xuwenxiong longtermprognosisofpatientswithhepatitisbvirusrelatedacuteonchronicliverfailurearetrospectivestudy
AT lixuejun longtermprognosisofpatientswithhepatitisbvirusrelatedacuteonchronicliverfailurearetrospectivestudy
AT chendabiao longtermprognosisofpatientswithhepatitisbvirusrelatedacuteonchronicliverfailurearetrospectivestudy
AT zhangyeqiong longtermprognosisofpatientswithhepatitisbvirusrelatedacuteonchronicliverfailurearetrospectivestudy
AT chenyuanli longtermprognosisofpatientswithhepatitisbvirusrelatedacuteonchronicliverfailurearetrospectivestudy
AT wangjuan longtermprognosisofpatientswithhepatitisbvirusrelatedacuteonchronicliverfailurearetrospectivestudy
AT luoqiumin longtermprognosisofpatientswithhepatitisbvirusrelatedacuteonchronicliverfailurearetrospectivestudy
AT xiechan longtermprognosisofpatientswithhepatitisbvirusrelatedacuteonchronicliverfailurearetrospectivestudy
AT pengliang longtermprognosisofpatientswithhepatitisbvirusrelatedacuteonchronicliverfailurearetrospectivestudy